Clinical trial
Study Evaluating Rimonabant Efficacy in Drug-NAive DiabEtic Patients
NCT00257257 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00257257 |
|---|---|
| Title | Study Evaluating Rimonabant Efficacy in Drug-NAive DiabEtic Patients |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose (Rimonabant 20 mg) Multicenter Study of Long-Term Glycemic Control With Rimonabant in Treatment-naïve Patients With Type 2 Diabetes |
| Acronym | SERENADE |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Rimonabant (SR141716) |
| Enrollment | 281 |
| Start date | Mar 1, 2005 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Nov 22, 2005 |
| Last update posted | Apr 20, 2009 |
| Countries | Argentina, Chile, Germany, Hungary, Netherlands, Poland, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: